机译:利拉鲁肽单药联合二甲双胍治疗日本超重/肥胖2型糖尿病的疗效和安全性
Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan;
Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan;
Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan;
Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan;
Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan;
Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan;
Department of Internal Medicine, Yokohama Municipal Citizens 'Hospital, Kanagawa, Japan;
Department of Internal Medicine, Eiju General Hospital, Tokyo, Japan;
Department of Internal Medicine, Japan Community Health Care Organization Saitama Medical Center, Saitama, Japan;
Department of Internal Medicine, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital, Tokyo, Japan;
Diabetes Center, Eiju General Hospital, Tokyo, Japan;
Department of Internal Medicine, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan;
Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan;
Liraglutide; Metformin; Type 2 diabetes; Japanese; Randomized controlled trial;
机译:利拉鲁肽单药联合二甲双胍治疗日本超重/肥胖2型糖尿病的疗效和安全性
机译:与二甲双胍相比,利拉鲁肽单药对日本超重/肥胖的2型糖尿病患者β细胞功能和胰腺酶的影响:KIND-LM随机试验的亚群分析
机译:每日一次的人类GLP-1类似物利拉鲁肽与格列本脲单药联合治疗在日本2型糖尿病患者中的疗效和安全性
机译:中料饮食对超重患者2型糖尿病预防疗效的综述
机译:糖尿病在精神疾病和2型糖尿病患者中患糖尿病护理的自我保健管理行为和障碍,与2型糖尿病的患者相比
机译:在单独使用二甲双胍或吡格列酮控制不充分的日本2型糖尿病患者中二肽基肽酶4抑制剂西他列汀与α-葡萄糖苷酶抑制剂相比的疗效和安全性(采用西他列汀1控制糖尿病的最终联合疗法研究):随机开放标签非劣效性试验
机译:利拉鲁肽单药和磺酰脲类联合疗法对日本2型糖尿病的安全性和有效性的回顾性分析:起始一年后剩余β细胞功能与HbA1c目标达成的关系